These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19754400)

  • 1. Half a century of L-DOPA.
    Mena MA; Casarejos MJ; Solano RM; de Yébenes JG
    Curr Top Med Chem; 2009; 9(10):880-93. PubMed ID: 19754400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-dopa therapy for Parkinson's disease: past, present, and future.
    Nagatsua T; Sawadab M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
    Del-Bel E; Bortolanza M; Dos-Santos-Pereira M; Bariotto K; Raisman-Vozari R
    Synapse; 2016 Dec; 70(12):479-500. PubMed ID: 27618286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
    LeWitt PA
    Mov Disord; 2015 Jan; 30(1):64-72. PubMed ID: 25449210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
    Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
    CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
    Paul R; Borah A
    Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.
    Navailles S; Carta M; Guthrie M; De Deurwaerdère P
    Cent Nerv Syst Agents Med Chem; 2011 Dec; 11(4):305-20. PubMed ID: 22117594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.
    Rodgers KJ; Hume PM; Morris JG; Dean RT
    J Neurochem; 2006 Aug; 98(4):1061-7. PubMed ID: 16771833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
    Nissinen E
    Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.